AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11835845
Drug: Local homoharringtonine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local homoharringtonine and dexamethasone treatment
Trial: 11835845
Drug: Local dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Local dexamethasone treatment
Trial: 11835845
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug treatment (untreated group)
Trial: 15278645
Drug: Alkalinized lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alkalinized lidocaine solution (pH 7.12)
Trial: 21459975
Drug: Group therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group therapy intervention (manual based developmental group therapy programme)
Trial: 15639688
Drug: EZE/SIMVA (10/10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZE/SIMVA (10/10, 10/20, 10/40, or 10/80 mg)
Trial: 10667618
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg/day, increased to 100 mg/day if necessary)
Trial: 10667618
Drug: Moclobemide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (300 mg/day, increased to 450 mg/day if necessary)
Trial: 343748
Drug: Intraluminal fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraluminal fluorouracil (30 mg/kg) with intravenous fluorouracil (10 mg/kg) on the first two postoperative days and five subsequent courses of oral fluorouracil (90 mg/kg) over one year.
Trial: 31264294
Drug: High-dose CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CBD co-administered with THC
Trial: 30450532
Drug: Chemotherapy (paclitaxel/carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (paclitaxel/carboplatin with or without bevacizumab)
Trial: 30450532
Drug: Leptin/adiponectin ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin/adiponectin ratio (L/A) before treatment
Trial: 21688658
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia with paracetamol, lornoxicam, and epidural ropivacaine (Group 1)
Trial: 21688658
Drug: Multimodal analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesia with paracetamol, epidural ropivacaine, and tramadol (Group 2)
Trial: 16430565
Drug: Gel lubrication
RxNorm normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel lubrication
Trial: 16430565
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No gel lubrication (control)
Trial: 11378806
Drug: High phenol
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High phenol diet (69 g per day of extra virgin olive oil rich in phenols)
Trial: 11378806
Drug: Low phenol
RxNorm normalized name: yellow phenolphthalein
DrugBank: Phenolphthalein (DB04824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low phenol diet (69 g per day of extra virgin olive oil poor in phenols)
Trial: 9463202
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 ml of 0.9% saline solution)
Trial: 10442378
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and UFT plus oral calcium folinate
Trial: 2198315
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg pefloxacin (PEFLO) once daily
Trial: 2198315
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg ofloxacin (OFLO) once daily
Trial: 2198315
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with WHO/MDT regimen
Trial: 31396794
Drug: Laser acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser acupuncture therapy (LAT)
Trial: 26066346
Drug: Atazanavir (ATV)
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Atazanavir (ATV) powder boosted with ritonavir (RTV) liquid plus optimized dual nucleoside reverse-transcriptase inhibitor (NRTI) background therapy
Trial: 21875474
Drug: Yanshu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yanshu injection combined with IMRT and concomitant chemotherapy
Trial: 21875474
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (IMRT and concurrent chemotherapy)
Trial: 19335225
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of hand cream (cornstarch and ethanol)
Trial: 16449273
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of acute bronchodilators
Trial: 15038168
Drug: Glucocorticosteroid administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucocorticosteroid administration
Trial: 11156667
Drug: Atrioventricular modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrioventricular modifying drugs and VVI pacemaker
Trial: 3538487
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg/day for 14 days)
Trial: 3538487
Drug: Steroid response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Steroid response
Trial: 24959794
Drug: Relaxation breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation breathing and progressive muscle relaxation (twice a day for 8 weeks)
Trial: 22428471
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl 25 microg plus hyperbaric bupivacaine 2.5 mg (Group BF)
Trial: 18523382
Drug: Mouth rinsing
RxNorm normalized name: phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouth rinsing solution (0.2% NaF)
Trial: 18523382
Drug: Tablet (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet (0.75 mg F)
Trial: 16419491
Drug: Levothyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine treatment (Group B)
Trial: 12585791
Drug: Slider-Board (SB)
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slider-Board (SB) therapy and Standardized Exercises (SEs)
Trial: 12585791
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (CPM, SB therapy, SEs)
Trial: 10539832
Drug: Platelet glycoprotein
RxNorm normalized name: PLATELET GLYCOPROTEIN VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet glycoprotein IIb/IIIa inhibitor (eptifibatide)
Trial: 1817618
Drug: Thiopentone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone 0.5 mg kg‐1
Trial: 1817618
Drug: Propofol 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.25 mg kg‐1
Trial: 30991137
Drug: Curcuma longa
RxNorm normalized name: Curcuma Longa
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuma longa (30 mg/kg/day)
Trial: 28799861
Drug: No intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: No intra-arterial therapy (COVES = 0)
Trial: 22664976
Drug: IDX375 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX375 200 mg BID
Trial: 22664976
Drug: IDX375 (25-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDX375 (25-200 mg single ascending doses)
Trial: 18718110
Drug: Multidisciplinary pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary pain treatment allocation protocol
Trial: 17578470
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (128 mg slow‐release magnesium stearate)
Trial: 31265756
Drug: Parenteral sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral sedation
Trial: 31265756
Drug: More than
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More than one type of parenteral sedation administered within 60 minutes
Trial: 28425449
Drug: Placebo-pill treatment
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-pill treatment
Trial: 25458637
Drug: rhG‐CSF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhG‐CSF plus empirical antibiotics (Group I)
Trial: 25458637
Drug: Empirical antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antibiotics alone (Group II)
Trial: 9205016
Drug: Nicorandil 5
RxNorm normalized name: nicorandil 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil 5 mg tid
Trial: 3330528
Drug: ST 567
RxNorm normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ST 567 3 X 30 mg
Trial: 3330528
Drug: Propranolol 3
RxNorm normalized name: HCTZ 25/PROPRANOLOL 30MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 3 X 40 mg
Trial: 30924578
Drug: basal-only insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: basal-only insulin
Trial: 28620916
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Ketamine 0.2 mg/kg, Ketamine 0.4 mg/kg, Saline)
Trial: 26571892
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) at Tianshu (ST 25), Fujie (SP 14) with dense‐disperse wave (2Hz/15 Hz, 0.1 to 1.0 mA) and Shangjuxu (ST 37) needled, treatment for 8 weeks (5 times weekly for first 2 weeks, 3 times weekly for next 6 weeks).
Trial: 26571892
Drug: Sham electroacupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham electroacupuncture (sham‐EA) at sites lateral to Tianshu (ST 25) and Fujie (SP 14), and shallow needling at lateral Shangjuxu (ST 37), treatment for 8 weeks (5 times weekly for first 2 weeks, 3 times weekly for next 6 weeks).
Trial: 18454508
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of peginterferon alpha-2a (180 microg/week) plus ribavirin (800 mg/day)
Trial: 18454508
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of peginterferon alpha-2a (180 microg/week) plus ribavirin (800 mg/day)
Trial: 11006795
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride 60 mg/day orally
Trial: 10163482
Drug: Jet spacer
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jet spacer with high-dose beclomethasone dipropionate (0.5 mg four times daily)
Trial: 10163482
Drug: Standard actuator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard actuator with high-dose beclomethasone dipropionate (0.5 mg four times daily)
Trial: 1614687
Drug: Anti-DIM medication,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-DIM medication, vitamins, and combined regimen
Trial: 6692967
Drug: Peroral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroral iron therapy (200 mg Fe++ daily)
Trial: 30926104
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) with orthodontic treatment
Trial: 30926104
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (simulated LLLT with orthodontic treatment)
Trial: 22892585
Drug: Avagacestat 25
RxNorm normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avagacestat 25 mg daily
Trial: 22892585
Drug: Avagacestat 50
RxNorm normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avagacestat 50 mg daily
Trial: 22892585
Drug: Avagacestat 100
RxNorm normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avagacestat 100 mg daily
Trial: 22892585
Drug: Avagacestat 125
RxNorm normalized name: Avagacestat
DrugBank: Avagacestat (DB11893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avagacestat 125 mg daily
Trial: 17389702
Drug: Lugol solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lugol solution treatment (group 1, n = 17)
Trial: 17389702
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative treatment with Lugol solution (group 2, n = 19)
Trial: 2269915
Drug: Autogenous bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autogenous bone implant
Trial: 29159691
Drug: Vehicle samples
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vehicle samples (aqueous (AQ) cream)
Trial: 19064973
Drug: Neoadjuvant docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2) every 3 weeks for two cycles, followed by cisplatin 40 mg/m(2)/wk concurrent with radiotherapy
Trial: 14997082
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 30 mg x kg(‐1)
Trial: 14997082
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 15 mg x kg(‐1) followed by infusion of 1 mg x kg(‐1) h(‐1)
Trial: 7751258
Drug: Lithium (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (mean optimal daily dose: 1,248 mg, mean serum level: 1.12 mEq/L)
Trial: 2346341
Drug: Biosynthetic human
RxNorm normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biosynthetic human growth hormone (r-hGH)
Trial: 341338
Drug: Clotrimazole 7-day
RxNorm normalized name: Quality Choice Clotrimazole 7-Day Treatment 1% Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 7-day treatment
Trial: 341338
Drug: Clotrimazole 14-day
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole 14-day treatment
Trial: 341338
Drug: Miconazole nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole nitrate 14-day treatment
Trial: 31612359
Drug: Inhaled methoxyflurane
RxNorm normalized name: methoxyflurane Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methoxyflurane 3 mL
Trial: 31612359
Drug: Standard analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard analgesic treatment (SAT) - IV morphine 0.1 mg/kg for severe pain (NRS ≥ 7); IV paracetamol 1 g or IV ketoprofen 100 mg for moderate pain (NRS 4-6)
Trial: 24749263
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 25) with multimodal analgesia (paracetamol, tramadol, ketoprofen)
Trial: 15927414
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (controls) excluding Grade 1 with superficial myometrial invasion
Trial: 10553846
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 9 mg with fentanyl 20 microg
Trial: 10553846
Drug: Plain bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain bupivacaine 9 mg with fentanyl 20 microg
Trial: 8744464
Drug: Ceftizoxime 1
RxNorm normalized name: ceftizoxime 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime 1 g every 12 hours for two doses
Trial: 8744464
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g every 24 hours for two doses
Trial: 6350878
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (azathioprine and prednisone)
Trial: 17657970
Drug: Aerosol therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol therapy using 'Dovolenskaya' mineral water
Trial: 7625344
Drug: 0.8 g.kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Trial: 7625344
Drug: 1.0 g.kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Trial: 7625344
Drug: 1.2 g.kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g.kg body wt-1.d-1 of a mixed protein diet (70% derived from vegetable sources)
Trial: 7625344
Drug: 1.2 g.kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g.kg body wt-1.d-1 of a high-quality mixed protein diet (80% from animal sources)
Trial: 29151701
Drug: Transcatheter selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter selective SMA urokinase infusion therapy
Trial: 21699794
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (FCM) in a maximum of 3 infusions of 1000 or 500 mg iron
Trial: 21699794
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (IS) with Ganzoni-calculated dosages in up to 11 infusions of 200 mg iron
Trial: 17531572
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus planned glycoprotein IIb/IIIa blockade
Trial: 11309551
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of furosemide plus 250 mg of probenecid
Trial: 11309551
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of furosemide plus 1000 mg of probenecid
Trial: 11309551
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 20 mg of furosemide
Trial: 9495430
Drug: Stress hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stress hormone cocktail (epinephrine, cortisol, glucagon, angiotensin II, and vasopressin) administered intravenously for 24 hours
Trial: 2666238
Drug: Nifuroxazide 400
RxNorm normalized name: nifuroxazide 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifuroxazide 400 mg twice daily for 5 days
Trial: 29665619
Drug: Pomegranate Extract
RxNorm normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate Extract (PE) - D2 (656 mg phenolics)
Trial: 28376767
Drug: 20,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20,000 IU vitamin D3 weekly
Trial: 26132895
Drug: 6.4% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% sucrose solution (SUC)
Trial: 21599832
Drug: High insertion
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High insertion torque implants (MIT > 70 Ncm, mean = 110.6 Ncm, range: 70.8‐176 Ncm)
Trial: 21599832
Drug: Low insertion
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low insertion torque implants (control group, MIT between 30 and 50 Ncm, mean = 37.1 Ncm)
Trial: 21436223
Drug: Sublingual cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual cannabis extract (maximum of 10.8 mg tetrahydrocannabinol and 10 mg cannabidiol)
Trial: 18472662
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment episode
Trial: 18472662
Drug: Additional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional treatment after initial outpatient episode
Trial: 18472662
Drug: Outpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatment only
Trial: 18472662
Drug: Various combinations
RxNorm normalized name: various combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various combinations of outpatient, intensive outpatient, and residential treatment
Trial: 10897061
Drug: IFN plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN plus NAC (3MU IFN-alpha thrice weekly plus NAC 1800 mg daily)
Trial: 1420739
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg famotidine nocte
Trial: 31728054
Drug: 24-hour intravenous
RxNorm normalized name: 24 Hour Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour intravenous methotrexate (IV MTX) infusion (1 g/m2)
Trial: 31728054
Drug: 4-hour intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-hour intravenous methotrexate (IV MTX) infusion (2 g/m2)